Abstracts tagged "Biologics and patient-reported outcome measures"

Abstract Number: 836 • ACR/ARP Annual Meeting 2019
Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results
Filip Van den Bosch¹, Lars-Erik Kristensen ², Dennis McGonagle ³, Maurizio Rossini ⁴, Soyi Liu-Leage ⁵, Christophe Sapin ⁵, Gabriella Meszaros ⁵ and Joseph Merola ⁶, ¹Ghent University Hospital, Ghent, Belgium, ²Copenhagen University Hospital, Bispebjerg-Frederiksberg, Denmark, ³University of Leeds, Leeds, United Kingdom, ⁴University of Verona, Verona, Italy, ⁵Eli Lilly and Company, Indianapolis, ⁶Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Therapeutic options for patients with PsA are increasing but data directly comparing biologics are limited. The multicentre, open-label SPIRIT-H2H trial (NCT03151551) evaluated the efficacy…